中文摘要：

中国既有研究中缺乏针对药品安全社会共治制度安排的研究，理论上对于药品安全与食品安全社会共治的制度安排有何区别存在研究盲点。本文从中国药品安全社会共治“预防一免疫一治疗”三级协同制度安排构建框架出发，分别对药品安全社会共治的“预防”体系的制度构建、“免疫”体系的制度构建及“治疗”体系的制度构建进行了分析和讨论。研究表明，无论在“预防”体系还是“免疫”体系下，或者在“治疗”体系下，药品安全社会共治制度安排的行动主体、行动情境、交互模式和潜在结果，都呈现出与食品安全社会共治不同的制度特征。在此基础上，本文对构建药品安全社会共治制度安排提出政策建议。研究结论可为中国药品安全社会共治从侧重事后“治疗”体系，向事后与事前“预防”和“免疫”体系平衡监管的方向转型实践，提供理论基础和策略依据。

英文摘要：

The existing literature lack the attention on the institutional analysis of drug safety social co-governance in China, and the institutional arrangement of food safety and drug safety should have difference. This paper uses the ＂ Precaution-Immune-Treatment＂ co-governance institutional arrangement framework, and analyze the ＂Precaution＂ System ＂Immune＂System and ＂Treatment＂ System individually. Result shows that compared with food safety social co-governance, all the three co-governance system show the difference in actor, contest, interaction and outcome in drug safety social co-governance. What＇s more, we come up with the policy suggestion for drug safety social co-governance in China. The conclusion of this paper is that China Drug safety social co-governance is transforming from concentrating on ＂Treatment＇System to ＂Precaution＂ System and ＂Immune＂ System.